ConductScience.org, home

Paper16732016

Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease.

Targher G and 8 others. Diabetes Care, 2006. Cited by 319 papers, by iCite.

Cite this record

ConductScience Library. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Papers, record 16732016. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16732016

Download JSON
Disease
type 1 diabetes mellitus304 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease.
PubMed
Journal
Diabetes Care
PubMed
Year
2006
PubMed
Publication types
Journal Article, Multicenter Study
PubMed
Citations, by iCite
319
iCite
Relative citation ratio, by iCite
8.12
iCite
Revised in PubMed
2022-03-11
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Targher GGiovanni
2Bertolini LLorenzo
3Padovani RRoberto
4Rodella SStefano
5Zoppini GGiacomo
6Zenari LLuciano
7Cigolini MMassimo
8Falezza GGiancarlo
9Arcaro GGuido

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carotid ArteriesMajor topic
Carotid Artery DiseasesMajor topic
Fatty LiverMajor topic
LiverMajor topic
Adult
Blood Glucose
Body Mass Index
Body Weight
Female
Humans
Male
Middle Aged
Triglycerides

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06348706Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 DiabetesResults

Source ClinicalTrials.gov

Download CSV of trials

Cited by147

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 319 citations.

PMIDTitleJournalYearIn PapersSource
41767367A pilot study on a combined non-invasive screening test for metabolic dysfunction-associated steatotic liver disease and type 2 diabetes.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/41767367PubMed
40123646Non-alcoholic fatty liver disease (NAFLD) and its association to cardiovascular disease: A comprehensive meta-analysis.JRSM Cardiovasc Dis2025https://conductscience.org/library/papers/40123646PubMed
39868507Association Between Liver Fibrosis and Risk of Incident Stroke and Mortality: A Large Prospective Cohort Study.J Am Heart Assoc2025https://conductscience.org/library/papers/39868507PubMed
39231620Cardiovascular Death and Liver Disease: Mortality Trends and Disparities.Clin Med Res2024https://conductscience.org/library/papers/39231620PubMed
39086662Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.Front Cell Dev Biol2024https://conductscience.org/library/papers/39086662PubMed
39011212
Association of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With an Increased Risk of Congestive Heart Failure in Hospitalized Patients With Cirrhosis: A Propensity Score-Matched Analysis.
Cureus2024https://conductscience.org/library/papers/39011212PubMed
38213666Clinical Management of Non-alcoholic Steatohepatitis and the Role of the Cardiologist.Eur Cardiol2023https://conductscience.org/library/papers/38213666PubMed
38068433How Cardiac Fibrosis Assessed via T1 Mapping Is Associated with Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.J Clin Med2023https://conductscience.org/library/papers/38068433PubMed
37764755New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk.Nutrients2023https://conductscience.org/library/papers/37764755PubMed
37701352Association of nonalcoholic fatty liver disease and carotid media-intima thickness: A systematic review and a meta-analysis.Health Sci Rep2023https://conductscience.org/library/papers/37701352PubMed
37675086Opportunistic screening at chest computed tomography: literature review of cardiovascular significance of incidental findings.Cardiovasc Diagn Ther2023https://conductscience.org/library/papers/37675086PubMed
37663203Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease.Diabetes Metab Syndr Obes2023https://conductscience.org/library/papers/37663203PubMed
37417238Management of Stroke in Patients With Chronic Liver Disease: A Practical Review.Stroke2023https://conductscience.org/library/papers/37417238PubMed
36008083Shared Mechanisms between Cardiovascular Disease and NAFLD.Semin Liver Dis2022https://conductscience.org/library/papers/36008083PubMed
35990786Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH).Can Liver J2022https://conductscience.org/library/papers/35990786PubMed
35557545Non-alcoholic Fatty Liver Disease Is Associated With Cardiovascular Outcomes in Subjects With Prediabetes and Diabetes: A Prospective Community-Based Cohort Study.Front Cardiovasc Med2022https://conductscience.org/library/papers/35557545PubMed
35467297General Overview About the Current Management of Nonalcoholic Fatty Liver Disease.Clin Drug Investig2022https://conductscience.org/library/papers/35467297PubMed
35264962Astragaloside IV Relieves Atherosclerosis and Hepatic Steatosis via MAPK/NF-κB Signaling Pathway in LDLR-/- Mice.Front Pharmacol2022https://conductscience.org/library/papers/35264962PubMed
35232007Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals.Clin Mol Hepatol2022https://conductscience.org/library/papers/35232007PubMed
34933963Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis.Open Heart2021https://conductscience.org/library/papers/34933963PubMed

See all 147 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
VILDAGLIPTINCHEMBL142703Results1https://conductscience.org/library/drugs/CHEMBL142703

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/16732016

GET https://conductscience.org/api/papers/v1/16732016/cited_by?page=2